Vijay Ivaturi

Vijay Ivaturi

Auto-generated profile, based on publicly available information

Vijay Ivaturi

Pumas‐AI, Inc Dover Delaware USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Journal of Clinical Anesthesia
Verified
Journal Article
Open access
JZJie Zhou
Jie Zhou
CLCathrine Leonowens
Cathrine Leonowens
VIVijay D. Ivaturi
Vijay D. Ivaturi
LLLauren L. Lohmer
Lauren L. Lohmer
LCLaura Curd
Laura Curd
VSVirginia Schmith
Virginia Schmith
To evaluate factors affecting variability in response to remimazolam in general anesthesia. Plasma concentration-time data from 11 Phase 1-3 clinical trials were pooled for the population pharmacokinetic (popPK) analysis and concentration-bispectral index (BIS) data were pooled from 8 trials for popPK-PD analysis. A 3-compartment model with allometric exponents on clearance and volume described remimazolam concentrations over time. An effect compartment model with an inhibitory sigmoid Emax model was fit to the concentration-BIS data. Simulations were performed to assess sedation in general anesthesia and post-surgical sedation in healthy and sensitive populations. General anesthesia and post-surgical sedation. 689 subjects included in popPK and 604 subjects included in popPK-PD. Most subjects (>85%) were ASA Class 1 or 2, with the remaining subjects being ASA Class 3. Serial plasma concentrations and BIS scores. Standard intra-operative monitoring. PopPK model included an effect of extracorporeal circulation, ASA class, and sex on PK and a time-dependent clearance (~30% lower at 24 h) that was not related to cumulative dose. Co-administered remifentanil had a synergistic decrease in BIS with remimazolam. Remimazolam IC50 increased with cumulative dose. Onset was faster in overweight subjects and slower in Asian subjects. If using a weight-based regimen, simulations showed that remimazolam 6 mg/kg/h until loss of consciousness followed by 1 mg/kg/h during general anesthesia and 0.25 mg/kg/h for post-surgical sedation for up to 24 h is optimal, regardless of ASA class or sensitivity of subjects. If using a weight-based regimen, results illustrated an appropriate regimen of remimazolam for general anesthesia and post-surgical sedation in general and sensitive populations, although lower doses can be considered in elderly patients with a significant disease burden or in ASA Class 3 patients. The time-dependent change in clearance is not clinically relevant for up to 24 h.

5 December 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ETElizabeth Tucker
Elizabeth Tucker
BGBeatriz Guglieri-Lopez
Beatriz Guglieri-Lopez
AOAlvaro Ordonez
Alvaro Ordonez
BRBrittaney Ritchie
Brittaney Ritchie
MKMariah H. Klunk
Mariah H. Klunk
SJSanjay Jain
Sanjay Jain
Tuberculous meningitis (TBM) is a devastating form of tuberculosis (TB), and key TB antimicrobials, including rifampin, have restricted brain penetration. A lack of reliable data on intralesional drug biodistribution in infected tissues has limited pharmacokinetic (PK) modeling efforts to optimize TBM treatments. Current methods to measure intralesional drug distribution rely on tissue resection, which is difficult in humans and generally limited to a single time point even in animals. In this study, we developed a multidrug treatment model in rabbits with experimentally induced TBM and performed serial noninvasive dynamic 11C-rifampin positron emission tomography (PET) over 6 weeks. Area under the curve brain/plasma ratios were calculated using PET and correlated with postmortem mass spectrometry. We demonstrate that rifampin penetration into infected brain lesions is limited, spatially heterogeneous, and decreases rapidly as early as 2 weeks into treatment. Moreover, rifampin concentrations in the cerebrospinal fluid did not correlate well with those in the brain lesions. First-in-human 11C-rifampin PET performed in a patient with TBM confirmed these findings. PK modeling predicted that rifampin doses (≥30 mg/kg) were required to achieve adequate intralesional concentrations in young children with TBM. These data demonstrate the proof of concept of PET as a clinically translatable tool to noninvasively measure intralesional antimicrobial distribution in infected tissues.

1 August 2013 in Epilepsy Research
Verified
Journal Article
Closed access
SASuresh K. Agarwal
Suresh K. Agarwal
RKRobert L. Kriel
Robert L. Kriel
RBRichard C. Brundage
Richard C. Brundage
VIVijay D. Ivaturi
Vijay D. Ivaturi
JCJames C. Cloyd
James C. Cloyd

1 October 2017 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
VIVijay Ivaturi
Vijay Ivaturi
CDChristopher C. Dvorak
Christopher C. Dvorak
DCDanna Chan
Danna Chan
TLTao Liu
Tao Liu
MCMorton J. Cowan
Morton J. Cowan
JLJanel Long-Boyle
Janel Long-Boyle
A prospective multicenter study was conducted to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of fludarabine plasma (f-ara-a) and intracellular triphosphate (f-ara-ATP) in children undergoing hematopoietic cell transplantation (HCT) and receiving fludarabine with conditioning. Plasma and peripheral blood mononuclear cells (PBMCs) were collected over the course of therapy for quantitation of f-ara-a and f-ara-ATP. Nonlinear mixed-effects modeling was used to develop the PK model, including identification of covariates impacting drug disposition. Data from a total of 133 children (median age, 5 years; range, .2 to 17.9) undergoing HCT for a variety of malignant and nonmalignant disorders were available for PK-PD modeling. The implementation of allometric scaling of PK parameters alone was insufficient to describe drug clearance, particularly in very young children. Renal impairment was predicted to increase drug exposure across all ages. The rate of f-ara-a entry into PBMCs (expressed in pmoles per million cells) decreased over the course of therapy, resulting in 78% lower f-ara-ATP after the fourth dose (1.7 pmoles/million cells [range, .2 to 7.2]) compared with first dose (7.9 pmoles/million cells [range, .7 to 18.2]). The overall incidence of treatment-related mortality (TRM) was low at 3% and 8% at days 60 and 360, respectively, and no association with f-ara-a exposure and TRM was found. In the setting of malignancy, disease-free survival was highest at 1 year after HCT in subjects achieving a systemic f-ara-a cumulative area under the curve (cAUC) greater than 15 mg*hour/L compared to patients with a cAUC less than 15 mg*hour/L (82.6% versus 52.8% P = .04). These results suggest that individualized model-based dosing of fludarabine in infants and young children may reduce morbidity and mortality through improved rates of disease-free survival and limiting drug-related toxicity. ClinicalTrials.gov Identifier: NCT01316549.

29 December 2015 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
TLTao Liu
Tao Liu
TLTamorah Lewis
Tamorah Lewis
EGEstelle Gauda
Estelle Gauda
JGJogarao Gobburu
Jogarao Gobburu
VIVijay Ivaturi
Vijay Ivaturi

1 February 2013 in Epilepsy Research
Verified
Journal Article
Closed access
VIVijay Ivaturi
Vijay Ivaturi
RKRobert Kriel
Robert Kriel
RBRichard Brundage
Richard Brundage
GLGordon Loewen
Gordon Loewen
HMHank Mansbach
Hank Mansbach
JCJames Cloyd
James Cloyd